Melbourne, Australia
Slogan: Next-generation lung delivery to protect every child from infections
Description: Viral respiratory illnesses in children are frequent and costly, amounting to up to $50M AUD annually. The most common identified cause, Respiratory Syncytial Virus (RSV), has no proven therapeutics or vaccines. MISTI aims to offer a nebuliser that is a first-in-class, low-cost, scientifically validated lung delivery system to provide rapid protection.
Industries: Biotechnology, Health Care
Headquarter: Australia
Last Investment: $120.00K Pre Seed Round investment at 15 September 2023
Last Investment Investors: StartMate
As a Healthcare and Biotechnology company based in Australia, Misti is focused on developing a next-generation lung delivery system to combat viral respiratory illnesses in children, specifically targeting the common cause, Respiratory Syncytial Virus (RSV). The company recently secured a $120.00K pre-seed investment from StartMate on 15 September 2023. With the significant unmet need in the market for therapeutics and vaccines for RSV, Misti presents itself as a promising venture with the potential to make a substantial impact in the healthcare industry, both in terms of addressing a critical health issue and as an attractive investment opportunity.
